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Summary
 
Interleukin (IL)-1 is a proinflammatory cytokine with pleiotropic effects in inflammation. IL-1
binding to its receptor triggers a cascade of signaling events, including activation of the stress-
activated mitogen-activated protein (MAP) kinases, c-Jun NH
 
2
 
-terminal kinase (JNK) and p38
MAP kinase, as well as transcription factor nuclear factor 
 
k
 
B (NF-
 
k
 
B). IL-1 signaling results in
cellular responses through induction of inflammatory gene products such as IL-6. One of the
earliest events in IL-1 signaling is the rapid interaction of IL-1 receptor–associated kinases,
IRAK and IRAK-2, with the receptor complex. The relative roles of IRAK and IRAK-2 in
IL-1 signaling pathways and subsequent cellular responses have not been previously deter-
mined. To evaluate the importance of IRAK in IL-1 signaling, IRAK-deficient mouse fibro-
blast cells were prepared and studied. Here we report that IL-1–mediated activation of JNK,
p38, and NF-
 
k
 
B were all reduced in embryonic fibroblasts deficient in IRAK expression. In
addition, IL-6 production in response to IL-1 was also dramatically reduced in IRAK-deficient
embryonic fibroblasts and in skin fibroblasts prepared from IRAK-deficient mice. Our results
demonstrate that IRAK plays an essential proximal role in coordinating multiple IL-1 signaling
pathways for optimal induction of cellular responses.
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I
 
nterleukin 1 (IL-1
 
a 
 
and IL-1
 
b
 
) plays an important role
in inflammation, acting locally and systemically to induce
other proinflammatory cytokines, chemotactic factors, ad-
hesion molecules, acute phase proteins, and fever (1). Ani-
mals that lack expression of IL-1 or IL-1 receptor have re-
duced inflammatory responses (2–5). Cellular responses to
IL-1 are mediated by a cascade of intracellular signaling
events including activation of the stress-activated mitogen-
activated protein (MAP)
 
1
 
 kinases, c-Jun NH
 
2
 
-terminal ki-
nase (JNK) and p38, as well as transcription factor nuclear
factor 
 
k
 
B (NF-
 
k
 
B) (6). Upon IL-1 binding, IL-1 receptor
type I forms a complex with IL-1 receptor accessory pro-
tein (7–9). IL-1 receptor–associated serine/threonine ki-
nase (IRAK), and a recently identified homologue, IRAK-2,
are rapidly recruited to this receptor complex via the adap-
tor protein MyD88 (10–13). IRAK becomes phosphory-
lated and subsequently interacts with TRAF6, a member of
the TNF receptor–associated factor (TRAF) family (13,
14). TRAF6 has been implicated in activation of both JNK
and NF-
 
k
 
B (14, 15). TRAF6 associates with NF-
 
k
 
B–induc-
ing kinase (NIK), a MAP 3 kinase–related protein that is
essential for TNF-
 
a
 
– and IL-1–mediated NF-
 
k
 
B activation
but has no effect on the activation of JNK or p38 (15–17).
NIK interacts with and may directly activate the recently
identified kinases of NF-
 
k
 
B inhibitor (I
 
k
 
B; 18–20). I
 
k
 
B ki-
nases are responsible for activation of NF-
 
k
 
B via phos-
phorylation of its inhibitory partners, the I
 
k
 
B proteins,
leading to their degradation by proteasomes (21).
IRAK and IRAK-2 are homologous to Pelle, a Dro-
sophila protein kinase identified genetically to be important
in dorsal–ventral pattern formation and in pathogen resis-
tance (22, 23). Pelle is essential for the activation of Dorsal,
an NF-
 
k
 
B–like protein which is mediated by Toll, an IL-1
 
1
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receptor homologue in Drosophila (24). The rapid IL-
1–dependent association of IRAK and IRAK-2 with the
IL-1 receptor complex and their homology to Pelle suggest
that IRAK and/or IRAK-2 may serve important functions
in initiating IL-1 signaling. However, the roles of IRAK
and IRAK-2 in activation of the multiple downstream IL-1
signaling pathways have not previously been determined.
To dissect the role of IRAK in IL-1 signaling pathways, we
disrupted the IRAK gene by homologous recombination
and prepared IRAK-deficient fibroblasts. IL-1-induced ac-
tivation of JNK, p38, and transcription factor NF-
 
k
 
B, and
subsequent induction of IL-6 was analyzed in IRAK-defi-
cient cells.
 
Materials and Methods
 
Preparation of IRAK Antibody.
 
Polyclonal rabbit antiserum to
IRAK was raised against a peptide (Bio-Synthesis, Inc., Lewis-
ville, TX) corresponding to the COOH-terminal amino acids
(657–677) of mouse IRAK protein (25).
 
Disruption of the IRAK Gene and Generation of IRAK-deficient
Mice.
 
Mouse IRAK clones were isolated from a 129/Ola mouse
genomic library. A 7-kb BamHI–EcoRI DNA fragment covering
the first 9 exons of the mouse IRAK gene was used to prepare the
knockout construct. A cassette containing a neomycin resistance
gene was used to replace a 940-bp region covering exon 5 to
exon 7 of the gene. A herpes simplex–thymidine kinase cassette
was placed at the 3
 
9
 
 end of the construct. The DNA construct
was introduced into E14 embryonic stem cells by electroporation.
Cells were cultured in the presence of 400 
 
m
 
g/ml G418 and 0.2
 
m
 
M gancyclovir. Embryonic stem cells with the disrupted gene
were detected by PCR and then confirmed by Southern hybrid-
ization using a DNA probe flanking the 3
 
9
 
 end of the construct.
Chimeric mice were generated from embryos injected with em-
bryonic stem cells. Germline mice were obtained from breeding
of chimeric male mice with C57BL/6J females. Germline female
mice heterozygous for the disrupted IRAK gene were identified
by PCR. IRAK-deficient male mice carrying only the disrupted
IRAK gene were obtained from cross-breeding of heterozygous
female mice with wild-type littermates.
 
Preparation of Embryonic Fibroblasts and Skin Fibroblasts.
 
To pre-
pare  embryonic fibroblasts (EFs), embryonic stem cells with the
disrupted IRAK gene were injected into C57BL/6J blastocysts
and transferred to pseudopregnant mice. Embryos at day 15 of
gestation were harvested. Fibroblast cell suspensions were pre-
pared by trypsin treatment of the minced embryonic tissues. Fi-
broblasts derived from embryonic stem cells were enriched by
culturing in DMEM with 10% FCS and 1 mg/ml G418. Fibro-
blasts after 3–4 wk of culture with G418 were used in these stud-
ies. Control EF cells with the wild-type IRAK gene were pre-
pared from embryos of CD8-deficient mice (26). To prepare skin
fibroblasts (SFs), mouse body skin was shaved, cut into small
pieces, and then subjected to trypsin treatment. SFs in cell sus-
pensions were cultured in DMEM with 10% FCS.
 
Cell Stimulation.
 
Control and IRAK-deficient cells (9 
 
3 
 
10
 
5
 
/
plate) were plated overnight in 100-mm cell culture plates with
DMEM containing 5% FCS. EF cells were kept in the presence of
200 
 
m
 
g/ml G418. Before each experiment, cells were starved in
serum-free DMEM for 4 h. The cells were then stimulated with
IL-1
 
b
 
 (R&D Systems, Minneapolis, MN) or TNF-
 
a
 
 (Genzyme
Corp., Cambridge, MA) at 37
 
8
 
C. After stimulation, cells were
scraped from the plates in ice-cold PBS and used immediately.
 
In Vitro Kinase Assay.
 
After stimulation, cells were lysed in
NP-40 lysis buffer (20 mM Hepes, pH 7.5, 150 mM NaCl, 1%
NP-40, and 1 mM Na
 
3
 
VO
 
4
 
) containing EDTA-free complete
protease inhibitor cocktail (Boehringer Mannheim Corp., India-
napolis, IN), centrifuged at 16,000 
 
g
 
 for 10 min, and precleared
twice with 50 
 
m
 
l of GammaBind G–Sepharose slurry (Pharmacia
Biotech, Piscataway, NJ). MAP kinases were immunoprecipitated
with 50 
 
m
 
l GammaBind G–Sepharose slurry and 2 
 
m
 
g polyclonal
rabbit antibody, specific for the 20 COOH-terminal residues of
p38
 
a
 
 or the 17 COOH-terminal residues of JNK1 (Santa Cruz
Biotechnology, Santa Cruz, CA). Immunoprecipitates were
Figure 1. Lack of IRAK ex-
pression in IRAK-deficient cells.
(A) Map of the mouse IRAK
gene and construct. A genomic
DNA fragment containing the 59
portion of the mouse IRAK
gene was used as the homolo-
gous region for recombination.
Exon 5 to exon 7 of the gene was replaced by a neomycin resistant gene
cassette (NEO). A herpes simplex–thymidine kinase gene (HSV-TK) was
placed 39 of the construct. Restriction sites are BamHI (B), EcoRI (E)
and SpeI (S). (B) Disruption of the single IRAK allele in male embryonic
stem cells. Genomic DNAs from embryonic stem cells with the wild-type
(1) or disrupted (2) IRAK gene were digested with EcoRI and hybrid-
ized to the DNA probe shown in A. The 12-kb DNA band of the wild-type
allele and the 2.6-kb band of the disrupted allele detected in hybridization
are also shown in A. (C) Absence of IRAK protein in IRAK-deficient
cells. Primary embryonic EF cells were prepared as described in the Mate-
rials and Methods. Proteins from control (1) and IRAK-deficient (2) EF
cells were separated by 10% SDS-PAGE and IRAK was detected by im-
munoblotting using an IRAK-specific antibody. Equal loading of proteins
was demonstrated by subsequent blotting with an antibody to extracellular
signal–regulated kinase 2 (ERK-2). 
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washed twice with NP-40 lysis buffer and twice with kinase reac-
tion buffer (25 mM Hepes, pH 7.5, 10 mM MgCl
 
2
 
, 10 mM
MnCl
 
2
 
, 20 mM 
 
b
 
-glycerophosphate, and 1
 
3
 
 EDTA-free com-
plete protease inhibitor cocktail). Kinase reactions were per-
formed for 20 min at 30
 
8
 
C in kinase reaction buffer containing
50 
 
m
 
M ATP and 5 
 
m
 
Ci 
 
g
 
-[
 
32
 
P]ATP (3,000 Ci/mmol; Amersham
Corp., Arlington Heights, IL) with 0.5 
 
m
 
g GST–MAP kinase–
activated protein kinase 2 (MAPKAPK2; Upstate Biotechnology,
Lake Placid, NY) as p38 substrate or 2 
 
m
 
g GST–c-JUN (BioMol,
King of Prussia, PA) as JNK1 substrate. Samples were boiled in
SDS sample buffer, electrophoresed in 10% Tris-Glycine poly-
acrylamide gels, and transferred to PVDF membranes (Novex,
San Diego, CA). Bands were quantified on a PhosphorImager
System (Storm 840; Molecular Dynamics Inc., Sunnyvale, CA).
Membranes were stained for p38 and JNK1 protein using the p38
and JNK1 antibodies described above and the Vistra ECF West-
ern blotting system (Amersham Corp.).
 
Western Blotting.
 
Western blot analyses were carried out as
previously described (27). For detection of IRAK and I
 
k
 
B-
 
a
 
 pro-
tein levels, NP-40 cell lysates (10
 
5
 
 cells /sample) were separated
on SDS-PAGE and transferred to nitrocellulose (MSI, Westboro,
MA). The filters were immunoblotted with IRAK antiserum (1:
1,000 dilution) or rabbit antibody to I
 
k
 
B-
 
a
 
 (Santa Cruz Biotech-
nology). The bands corresponding to specific proteins were de-
tected by horseradish-peroxidase–conjugated rabbit IgG and en-
hanced chemiluminescence (Amersham Corp.).
 
NF-
 
k
 
B Mobility Shift Assay.
 
After stimulation, the cells from
100-mm plates were suspended in 500 
 
m
 
l of Buffer A (10 mM
Hepes, pH 7.9, 10 mM KCl, 100 
 
m
 
M EDTA, 100 
 
m
 
M EGTA,
1 mM dithiothreitol (DTT), and 500 
 
m
 
M PMSF) and incubated
on ice for 15 min. After adding 30 
 
m
 
l of 10% NP-40, the samples
were centrifuged at 14,000 rpm at 4
 
8
 
C for 30 s. The pellet was
washed once with buffer A and resuspended in 50 
 
m
 
l of buffer B
(20 mM Hepes, pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1 mM DTT, and 1 mM PMSF) for 30 min at 4
 
8
 
C. Nu-
clear extracts were obtained by centrifugation of the samples at
14,000 rpm for 10 min. Protein concentrations were measured by
the BCA method (Pierce, Rockford, IL). The consensus double-
stranded oligonucleotide for NF-
 
k
 
B binding (Santa Cruz Bio-
tech) was labeled by T4 polynucleotide kinase. The nuclear bind-
ing reaction was carried out with 5 
 
m
 
l of nuclear extract (10 
 
m
 
g),
1 
 
m
 
l of Poly(dI-dC), 1 
 
m
 
l of labeled probe (100,000 cpm), 5 
 
m
 
l
4
 
3
 
 buffer (20 mM Hepes, pH 7.9, 20 mm MgCl
 
2, and 1 mM
EDTA) and 8 ml of 25% glycerol for 30 min at room tempera-
ture. The binding complexes were separated on 6% polyacryl-
amide gel in 0.53 Tris-buffered EDTA (Novex) and detected by
autoradiography.
Northern Blot Analysis and IL-6 ELISA. For IL-6 mRNA de-
tection, EF cells cultured in 100-mm plates were treated with IL-1b
or TNF-a for 3 h at 378C. Total RNA was extracted from EF
cells with RNAzol (Tel-Test, Inc., Friendswood, TX). Northern
blot analysis was performed as previously described (28) using a
mouse IL-6 cDNA probe prepared by PCR from commercial
mouse IL-6 cDNA template and oligonucleotides (Clontech,
Palo Alto, CA). For detection of secreted IL-6 protein, EF (5 3
104 /well) and SF (104/well) cells were incubated overnight in
flat-bottomed microtiter plates in 10% FCS-DMEM. After a 2–4-h
incubation with low endotoxin 1% FCS-RPMI-1640 medium
(Sigma Chemical Co., St. Louis, MO), cells were treated for 8 h
with mouse IL-1b in fresh medium. Supernatants were then col-
lected and analyzed for IL-6 using commercial ELISA kits (from
Endogen, Inc., Woburn, MA, or Genzyme Corp.), with recom-
binant mouse IL-6 as a standard.
Results and Discussion
IRAK-deficient Cells. To investigate whether IRAK is
indispensable for IL-1 signaling pathway, IRAK-deficient
mouse primary EF cells were prepared from mouse em-
Figure 2. Defective IL-1–induced p38
and JNK activation in IRAK-deficient EF
cells. IRAK-deficient (2) or control (1) EF
cells were stimulated with IL-1b (0.1–10
ng/ml) or TNF-a (100 ng/ml) for 10 min
at 378C, and immune complex kinase assays
for p38 and JNK1 activity were performed.
(A) Phosphorylation of MAPKAPK2 by
immunoprecipitated p38 and of c-Jun by
immunoprecipitated JNK1. Western blot-
ting for p38 and JNK1 was performed as a
loading control. (B) Quantitation of p38
and JNK1 activation. p38 and JNK1 kinase
assays were quantitated by PhosphorImager
(Molecular Dynamics), and normalized to
the amount of p38 or JNK1 detected by
Western blotting for each sample and to the
activity in unstimulated IRAK-deficient EF
cells for each assay. The p38 data are repre-
sentative of three experiments, and the
JNK1 data are expressed as an average of
two experiments.2076 IRAK Requirement for Optimal Interleukin 1 Signaling
bryos injected with embryonic stem cells carrying a dis-
rupted IRAK gene as described in Materials and Methods.
The IRAK gene was disrupted by deletion of exons 5–7,
which encode the NH2-terminal portion of the kinase do-
main, subdomains I–V, including conserved amino acids
involved in ATP binding (Fig. 1 A). The deletion was con-
firmed by Southern hybridization (Fig. 1 B). Detection of
only the disrupted IRAK allele in male embryonic stem
cells suggests that the mouse IRAK gene is located on the
X chromosome. Consistent with our finding, the human
IRAK gene was also reported to be on the X chromosome
(EMBL/GenBank’DDBJ accession number U52112). The
absence of IRAK protein in EF cells containing the dis-
rupted IRAK allele was demonstrated by immunoblotting
with an anti-IRAK antiserum (Fig. 1 C). The lack of
IRAK expression in IRAK-deficient EF cells enabled us to
evaluate the importance of IRAK in IL-1 signaling.
Defective Activation of JNK and p38 in IRAK-deficient
Cells. JNK and p38 are strongly activated by IL-1, TNF-a,
cell stress, and LPS (29–33). JNK phosphorylates the transac-
tivation domain of c-Jun, which is involved in the activation
of activator protein 1–dependent genes, including genes in-
volved in inflammatory responses (29–31). p38 is also in-
volved in activation of gene expression and protein synthesis
during inflammation, including IL-1–induced IL-6 and pros-
taglandin  synthesis (34). The proximal events responsible
for IL-1–induced JNK and p38 activation are only partially
understood. We therefore compared IL-1–induced activa-
tion of JNK and p38 in IRAK-deficient and control EF cells.
JNK activity was measured by in vitro kinase assays of JNK
immunoprecipitates, using c-Jun as substrate. Activation of
JNK was reduced in IRAK-deficient cells by two- to three-
fold at all concentrations of IL-1 tested, although not com-
pletely eliminated (Fig. 2). This defect in JNK activation was
IL-1 specific, since TNF-a–induced JNK activity was com-
parable in control and IRAK-deficient cells. Activation of
p38 was measured in p38 immunoprecipitates using MAP-
KAPK-2 as a substrate. IL-1–induced activation of p38 was
also reduced in IRAK-deficient cells compared with control
cells, by three- to fivefold at all concentrations of IL-1 tested.
In contrast, TNF-a–induced p38 activity was similar in con-
trol and IRAK-deficient cells (Fig. 2). These results demon-
strate that IL-1–induced JNK and p38 activities are both spe-
cifically reduced in IRAK-deficient cells, and implicate
IRAK as the most proximal signaling component in the acti-
vation of the JNK and p38 pathways.
Defective Activation of NF-kB. IL-1 and TNF-a are the
two most efficient activators of the NF-kB family of tran-
scription factors (21, 35). NF-kB remains in an inactive
state when sequestered by IkB in the cytoplasm. Phosphor-
ylation of IkB by IkB kinases leads to ubiquitination and
subsequent degradation of IkB by proteasomes (18–21).
Released NF-kB is then translocated to the nucleus, where
it binds to regulatory sites in NF-kB–induced genes (21).
IkB levels in IRAK-deficient cells and control cells treated
with IL-1 were determined by immunoblotting with an
IkB-a–specific antibody. At concentrations of IL-1 ranging
from 10 pg/ml to 1 ng/ml, IkB degradation was signifi-
cantly less in IRAK-deficient cells as compared with con-
trol cells (Fig. 3 A). However, at 10 ng/ml IL-1, IkB-a
was degraded almost completely in both IRAK-deficient
and control cells. IL-1 induction of the NF-kB pathway
was further investigated by examining NF-kB DNA-bind-
ing activity in nuclear extracts (Fig. 3 B). Significant reduc-
tion in NF-kB activation was observed in IRAK-deficient
Figure 3. Reduced activation of the NF-kB pathway by IL-1 in
IRAK-deficient cells. (A) Inefficient IkB degradation in IRAK-deficient
EF cells. Control (1) and IRAK-deficient (2) cells were stimulated with
IL-1 for 15 min at 378C. Proteins in cell lysates were separated on SDS-
PAGE and IkB was detected with an IkB-a–specific antibody. Equal
amounts of sample loading were demonstrated by subsequent blotting of
the same filter with an antibody specific to extracellular signal–regulated
kinase 2 (ERK-2). The intensity of the protein bands was quantitated by
densitometry. The amount of IkB in the IL-1–stimulated cells is ex-
pressed as the percentage of that in unstimulated cells. (B) Decreased activa-
tion of NF-kB by IL-1 in IRAK-deficient cells. EF cells were stimulated
with IL-1 or TNF-a for 30 min at 378C. Nuclear extracts were prepared
and NF-kB DNA-binding activity was determined with the electro-
phoretic mobility shift assay. The data are representative of two indepen-
dent experiments with similar results.2077 Kanakaraj et al.
cells at low IL-1 concentrations. Consistent with the results in
IkB degradation, NF-kB activation was comparable in con-
trol and IRAK-deficient cells at high IL-1 concentrations.
Defective Induction of IL-6. IL-1 signaling triggers cellu-
lar responses through the induction of various inflamma-
tory gene products (1). IL-6 is strongly induced by IL-1 via
activation of transcription factors including NF-kB and ac-
tivator protein 1, which bind to the enhancer elements of
the IL-6 gene promoter (6). IL-6 in turn plays a crucial role
in inflammation by mediating acute phase reactions (36).
To determine whether the observed defects in IL-1–acti-
vated signaling result in impaired cellular responses, IL-6
induction in response to IL-1 was measured. Levels of IL-6
mRNA induced by various concentrations of IL-1 were
significantly lower in IRAK-deficient EF cells compared
with control cells (Fig. 4 A). Similar decreases were also
found in IL-6 secreted from IRAK-deficient cells com-
pared with control cells (Fig. 4 B, top), and at various times
after IL-1 treatment (data not shown). In three indepen-
dent experiments, IL-6 induction by IL-1 was reduced by
three- to sixfold. Thus, the reduced IL-1 signaling in
IRAK-deficient cells results in decreased IL-6 production.
To confirm the defects in IL-1 signaling and cellular re-
sponse observed in IRAK-deficient EF cells, SF cells were
obtained from mice deficient in IRAK expression, as de-
scribed in Materials and Methods. Consistent with the ob-
servation in EF cells, IL-1–induced IL-6 production was
significantly decreased in IRAK-deficient SF cells com-
pared with SF cells prepared from wild-type mice (Fig. 4 B,
bottom). IL-1–induced JNK activation and IkB degradation
were also found to be defective in IRAK-deficient SF cells
(data not shown).
Role of IRAK in Regulating Multiple IL-1 Signaling Path-
ways. Taken together, our data demonstrate that IRAK
plays an important role in activating multiple IL-1 signaling
pathways that lead to the induction of IL-1–responsive
gene products such as IL-6. In the absence of IRAK, in-
duction of JNK and p38 activities was significantly reduced
at all concentrations of IL-1 tested, although not com-
pletely eliminated. Our results suggest that IRAK is re-
quired for optimal induction of JNK and p38 kinases and
that loss of its function cannot be completely compensated
for by IRAK-2 or other related kinases. Activation of JNK
and p38 have been reported to be mediated by cascades of
upstream kinases including MAP-2, MAP-3, and MAP-4
kinases (29). It remains to be determined at which levels
within these cascades IRAK may act to induce JNK and
p38 activity.
In contrast to the effects on JNK and p38, defects in NF-kB
activation in IRAK-deficient cells could be overcome by
high concentrations of IL-1. Our interpretation is that re-
lated kinases such as IRAK-2 may be able to fully activate
the NF-kB pathway under these conditions. However, in-
duction of cellular response to IL-1, such as IL-6 produc-
tion, is dramatically reduced in IRAK-deficient cells even
at high IL-1 concentrations. This suggests that activation of
NF-kB alone is not sufficient for optimal induction of
IL-1–mediated cellular responses. Induction of IL-6 and
other IL-1–responsive gene products may be mediated syn-
ergistically by multiple pathways, including activation of
NF-kB, and JNK/p38-mediated pathways. In the case of
IL-6 secretion, the dramatic decrease in its induction by IL-1
in IRAK-deficient cells, even in the presence of full activa-
tion of NF-kB DNA-binding activity, may result from de-
Figure 4. Decreased induc-
tion of IL-6 by IL-1 in IRAK-
deficient cells. (A) Decreased
induction of IL-6 mRNA in
IRAK-deficient cells. Control
(1) and IRAK-deficient (2)
EF cells were treated with IL-1
or TNF-a for 3 h at 378C. IL-6
mRNA expression in different
samples was detected by
Northern hybridization and
quantitated on a PhosphorIm-
ager. (B) Decreased induction
of secreted IL-6 in IRAK-defi-
cient cells. Control (1) and
IRAK-deficient (2) EF (top)
and SF (bottom) cells were stim-
ulated with IL-1 for 8 h at
378C. The amount of secreted
IL-6 in culture supernatants
was determined by ELISA.2078 IRAK Requirement for Optimal Interleukin 1 Signaling
creased activation of JNK/p38-dependent signaling path-
ways. This possibility is supported by a recent report that
p38 and other MAP kinases are involved in TNF-induced
IL-6 gene expression via modulation of transactivation po-
tential of NF-kB without affecting its DNA binding activ-
ity (37).
Our observation of significant reduction in multiple sig-
naling pathways and in IL-6 production induced by IL-1 in
IRAK-deficient cells suggests that inhibitors of IRAK or
IRAK-related kinases may be therapeutically useful for the
treatment of IL-1–mediated inflammatory diseases.
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